EDITORIAL SECTION
-
STRATEGY
Smarter Pharma
Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solution
-
CLINICAL TRIALS
Why Clinical Trials Need Digital Endpoints
According Citeline the average success rate for bringing a Phase candidate to market has dropped to an alltime low of just
-
MANUFACTURING
Ensuring Quality and Compliance in Biopharma
Ensuring quality and regulatory compliance in the biopharmaceutical industry is critical to safeguarding product safety and efficacy
-
Information Technology
The Cost of Bad Data
Modern pharmaceutical research generates an unprecedented volume of information Data from genomic sequencing
-
Biopharma
Reimagining Global Biomanufacturing Capacity with Continuous and Modular Systems
Biotechnology is fueling the ongoing expansion of the global market for a broad array of goods
-
EXPERT Talk
What Changes at Scale, and How Do You Know?
A pharmaceutical process that performs reliably on a few grams of material can behave very differently at pilot or commercial scale The temperature setpoint that worked on the bench the mixing time that delivered a uniform blend the feed rate that kept a reaction on track none of these is guaranteed to mean the same thing in larger equipment When that difference goes...
Advisory Board
KNOWLEDGE BANK
-
Articles
From Visibility to Decision Readiness: The Next Phase of Quality Maturity in Pharma
Over the past decade pharmaceutical organisations have made strong progress in both digitising and digitalising quality operations Systems such as laboratory information management systems LIMS manufacturing execution systems MES and electronic quality management systems eQMS have strengthened traceability embedded workflows and enabled real time visibility across quality processes
Combination Immunotherapy Trials: Designing the Next Generation of Cancer Drugs
For most of the past ten years the prevailing strategy in immunooncology was addition Checkpoint blockade delivered durable remissions in a minority of patients the intuitive fix was to attach a second agent to a PD or PDL backbone and watch whether response rates moved
Impact of Continuous Manufacturing on Pharmaceutical Efficiency and Quality
For most of its history the pharmaceutical industry has made medicines the way a bakery makes bread one batch at a time with pauses between each step for holding sampling and release testing That model served the sector well when blockbuster volumes and generous margins could absorb its inefficiencies Today neither condition holds European manufacturers face pricing pressure from payers persistent...
Crafting Cures: The Future of Drug Manufacturing
Behind every tablet that eases pain every vial that holds a lifesaving vaccine and every infusion that battles a chronic disease lies a complex and remarkable story It is a story of scientific discovery but more fundamentally
The Architect of the Void: When 3D Printing Becomes the Body’s New Bone
In the quiet pressurised hum of a modern surgical suite a surgeon holds a highdefinition scan of a young patients femur On the screen a jagged dark shadow marks where an osteosarcoma has claimed its territory For decades the script for this moment has been written in cold hard steel
Strategic Risk Management in Pharmaceutical Supply Networks
Ask a European pharmaceutical executive team how many qualified suppliers stand behind its ten highestvalue products and the answer arrives quickly and precisely Ask how many of those suppliers would still be shipping if a single industrial estate lost power for six weeks and the room falls silent That silence is the strategic problem in one sentence
-
Techno Trends
Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein
Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue
-
Projects
SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing
SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more
-
Research Insights
A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG
PIGACDG is a congenital disorder of glycosylation caused by pathogenic partial lossoffunction variants in the PIGA gene PIGA encodes an enzyme responsible for the catalytic transfer of Nacetylglucosamine
-
whitepaper
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys
TOP ARTICLES
-
1
Combination Immunotherapy Trials: Designing the Next Generation of Cancer Drugs
Lakshmi
Combination immunotherapy is now a portfolio necessity, yet late-stage combination trials in oncology continue to fail at an uncomfortable rate. This article examines why attaching a second immune tar...
-
2
Impact of Continuous Manufacturing on Pharmaceutical Efficiency and Quality
Lakshmi
Continuous manufacturing is moving from pilot curiosity to boardroom priority in the pharmaceutical sector. By replacing stop-start batch operations with integrated, real-time production, it compresse...
-
3
Crafting Cures: The Future of Drug Manufacturing
Dr. Amrish Chandra
Drug manufacturing transforms scientific discoveries into safe, effective therapies. Emerging technologies such as continuous manufacturing, artificial intelligence, real-time monitoring, and digital...
-
4
The Architect of the Void: When 3D Printing Becomes the Body’s New Bone
Baher A. Daihom
This article explores the transformative role of 3D bioprinting in treating bone cancer. By integrating patient-specific scaffolds with localised, time-released chemotherapy and osteoinductive bio-ink...
-
5
Strategic Risk Management in Pharmaceutical Supply Networks
Lakshmi
Europe's pharmaceutical supply disruptions increasingly arise not from single supplier failures but from hidden correlations between suppliers that appear independent. This article argues that pha...
press releases Read more...
Sino Biological Introduces AI-Trusted and Qualified Target Protein Collections for AI-Driven Discovery
As AI accelerates recombinant protein and antibody discovery for therapeutic and diagnostic development access to wellcharacterized target proteins is essential for evaluating AIdesigned molecules Sino Biological Inc Shenzhen Stock Exchange SZ a global biotechnology company
Sanofi’s next-generation rabies vaccine, VaxRabeo, approved in the EU for all ages
Sanofi announced today that the European Commission has approved VaxRabeo rabies virus inactivated strain Wistar for preexposure prophylaxis PrEP and postexposure prophylaxis PEP against rabies for all age groups
Datapharm appoints healthcare leaders to help shape the future of trusted medicines information
Datapharm the company behind emc the UKs trusted source of regulatorapproved medicines information today announced the formation of its Strategic Advisory Board bringing together senior figures from across pharma medical affairs and patient advocacy
London Biotechnology Show 2026 Concludes Two-Day Event, Bringing Global Life Sciences Community Together
The third edition of the London Biotechnology Show has concluded at ExCeL London following two days of discussions technology showcases and industry engagement that brought together stakeholders from across the global biotechnology and life sciences ecosystem
Events Read more...
24 - 27
Nov 2026Pharmtech & Ingredients 2026
Crocus Expo, Pavilion 2, Mosco...
24 - 25
Nov 2026BioPharma Deals Conference 2026
Science Congress Center, Munic...
25 - 25
Nov 2026What’s Next for Pharma Marketing in 2027
Landesmuseum Zürich, Zurich, S...
26 - 28
Nov 2026One Health Conference 2026
Thapar Institute of Engineerin...
01 - 03
Dec 2026Pharmaceutical Launch Excellence Summit
Novotel Amsterdam City, Nether...
01 - 03
Dec 202610th Antifibrotic Drug Development
Boston, MA at the Hotel Common...
02 - 04
Dec 2026Genome Informatics 2026
Wellcome Genome Campus, UK
03 - 04
Dec 2026Pharmacy and Pharmaceutical Conference
Madrid, Spain
LATEST NEWS Read more...
DISCO Pharmaceuticals Partners with AbbVie to Develop Next-Generation Bispecific Therapies for Solid Tumours
DISCO Pharmaceuticals has entered into a strategic collaboration and optiontolicense agreement with AbbVie to discover and develop nextgeneration ANDgated bispecific therapies for solid tumours with significant unmet medical needs
CAI Enters Agreement with PQE Group to Expand Global Life Sciences Services
CAI a professional services firm specialising in operational readiness and excellence for life sciences and other critical industries has entered into a definitive agreement with PQE Group a global consulting firm focused on quality compliance
Erasca Partners with Bristol Myers Squibb to Study ERAS-0015 Combination Therapy for Pancreatic Cancer
Erasca Inc a clinicalstage precision oncology company focused on developing treatments for cancers driven by the RASMAPK signalling pathway has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb BMS
Libtayo Receives EU Approval for Extended Dosing and Shorter Infusion Times Across Six Cancer Indications
Regeneron Pharmaceuticals has received European Commission EC approval for an alternative dosing schedule for Libtayo cemiplimab across all six of its approved indications for skin lung and cervical cancers in the European Union EU
FDA approves Roche’s Wilserdly for ER-positive, ESR1-mutated advanced breast cancer
Roche has received approval from the US Food and Drug Administration FDA for Wilserdly giredestrant in combination with everolimus to treat adults with oestrogen receptor ERpositive human epidermal growth factor receptor HERnegative ESRmutated locally advanced or metastatic breast cancer
European Commission approves Revolution Medicines’ RASONQUE for metastatic pancreatic cancer
Revolution Medicines has received European Commission EC approval for RASONQUE daraxonrasib to treat adults with metastatic pancreatic adenocarcinoma who have received at least one previous systemic therapy The medicine is taken once daily as an oral tablet and is approved for patients with or witho...









